Design, Synthesis and Biological Evaluation of 3,9-diazatetraasteranes as Novel Matrilysin Inhibitors
摘要:
Matrilysin is an ideal biological target to develop novel inhibitors because it is overexpressed in malignant tumour cells. A series of 3,9‐diazatetraasteranes was designed as inhibitors of matrilysin, which was an ideal biological target because it is responsible for aggressive malignant phenotypes and poor prognoses implicated in many cancers. Docking simulation supported the initial pharmacophore hypothesis and suggested a common interaction mechanism of 3,9‐diazatetraasteranes with the catalytic site of matrilysin. The 3,9‐diazatetraasteranes were synthesized by the photocyclization of 4‐aryl‐1,4‐dihydropyridines, and their structures were determined using 1H NMR, 13C NMR and MS. The inhibitory activities of these compounds on matrilysin were investigated in vitro using an MTT assay in A549 (small cell lung cancer) cells. The results show that the 3,9‐diazatetraasteranes can inhibit the growth of A549 tumour cells. The best IC50 value is approximately 50 μm. This result indicates that 3,9‐diazatetraasteranes will be useful pharmacological tools for the investigation of matrilysin inhibitors.
We have successfully synthesized 3,4,5-substituted 1,4-dihydropyridines (1,4-DHPs) from amine hydrochloride salts, aldehydes, and acetals in good yields without the addition of a catalyst. The synthesized 1,4-DHPs exhibit various wavelengths of fluorescence, which could be tuned by changing the substituents at the 3- and 5-positions of the 1,4-DHPs.
deacetylases have emerged as potential therapeutic targets for treatment of human illnesses such as cancer, metabolic, cardiovascular, and neurodegenerative diseases. The benefits of sirtuin modulation by small molecules have been demonstrated for these diseases. In contrast to the discovery of inhibitors of SIRT1, -2, and -3, only activators for SIRT1 are known. Here, we rationalized the potential of
NAD +依赖的沉默调节蛋白脱乙酰基酶已经成为治疗人类疾病如癌症,代谢,心血管和神经退行性疾病的潜在治疗靶标。对于这些疾病,已经证明了通过小分子调节瑟土因的益处。与SIRT1,-2和-3抑制剂的发现相反,仅SIRT1的激活剂是已知的。在这里,我们在合理化显影沉默调节蛋白的配体的前所未见的二氢吡啶骨架的电位,因此,我们制备了一系列1,4-二氢吡啶基衍生物的1 - 3。对它们的SIRT1-3脱乙酰基酶活性的评估表明,二氢吡啶结构的N1位上的取代基对Sirtuin活性的重要性。环丙基,苯基或苯乙基位于N1处赋予了非选择性SIRT1和SIRT2抑制活性,而苄基位于N1处赋予了有效的SIRT1,-2和-3激活。用小鼠C2C12成肌细胞进行的hMSC和线粒体功能研究进行的衰老分析证实了该化合物的新颖独特的SIRT激活特性。
One-Pot Synthesis of N-Substituted 4-Aryl-1,4-dihydropyridines Under Solvent-Free Conditions and Microwave Irradiation
作者:Saeed Balalaie、Elahe Kowsari
DOI:10.1007/s007060170012
日期:2001.12
The three-component condensation of benzaldehyde derivatives, alkyl propiolates, and primary amines catalyzed by silicagel, zeolite HY, montmorillonite K-10, and acidic alumina undermicrowaveirradiation gave N-substituted 4-aryl-1,4-dihydropyridines in short reaction times and high yields. The best results were obtained with silicagel.
Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors
作者:A Hilgeroth
DOI:10.1016/s0223-5234(01)01228-4
日期:2001.4
A first series of novel N-alkyl substituted syn dimeric4-aryl-1,4-dihydropyridines 12--17 have been synthesised and evaluated as HIV-1 protease inhibitors in in vitro assays. While the N-methyl derivatives 12 and 13 were almost inactive, with IC(50)-values of about 225 microM, the N-benzyl compounds with varied ester groups all exhibited stronger activities, with IC(50)-values of 11--12 microM for
Synthesis and Biological Evaluation of the First <i>N</i>-Alkyl Cage Dimeric 4-Aryl-1,4-dihydropyridines as Novel Nonpeptidic HIV-1 Protease Inhibitors
A first series of novel NH and N-alkyl-substituted cage dimeric4-aryl-1,4-dihydropyridines 3a-f has been synthesized and evaluated as HIV-1 protease inhibitors in in vitro assays. While the NH and N-methyl derivatives 3a,b,e,f were almost inactive with IC(50) values of about 200 microM, the N-Benzyl compounds exhibited stronger activity with an IC(50) value of 16.2 microM for the presently best compound